Grifols

Grifols and Beckman Coulter have entered into an exclusive, long-term agreement for the global distribution of Grifols' hemostasis instruments, reagents and consumables.

Grifols has signed an agreement to exclusively manufacture and supply plasma-derived products for the biosurgery field to Ethicon Inc., with an initial term of 10 years and subsequent 5-year renewal periods.

Grifols is currently building an $80 million manufacturing facility to optimize production and expand capacity for diagnostic testing solutions.

Grifols has restated its 2005 agreement with OraSure Technologies for a five-year extension to supply recombinant antigens for OraSure's OraQuick HCV Rapid Antibody Test.